Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of HLA-A*24:02 allele to detecting person drug eruptionrisk caused by metronidazole

An HLA-A, allele technology, applied in the field of biomedicine, can solve the problems of high mortality and morbidity, severe morbidity, personal and social burden, etc.

Active Publication Date: 2019-04-16
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition to causing common drug eruptions, metronidazole can also cause fatal severe drug eruptions. The latter has severe morbidity, high mortality and disability rates, and often brings a huge burden to individuals and society
[0004] There is currently no reliable means of predicting metronidazole-induced drug eruption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of HLA-A*24:02 allele to detecting person drug eruptionrisk caused by metronidazole
  • Application of HLA-A*24:02 allele to detecting person drug eruptionrisk caused by metronidazole

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. HLA-A*24:02 allele is a risk genetic marker for drug eruption caused by metronidazole

[0031] 1. Sample

[0032] The samples were human peripheral blood, including samples of metronidazole-induced drug eruption, samples of metronidazole-resistant patients, and samples of healthy controls.

[0033] 1. Drug eruption group caused by metronidazole

[0034] 15 patients with drug eruption caused by metronidazole (drug eruption group); the average age of the patients was 43.80±14.84 years old, the ratio of male to female was 2:13; the incubation period of metronidazole was 7.21±5.07 days (1-15 days). The main way for patients to use metronidazole was oral administration (10 cases), followed by external application (3 cases), and intravenous injection (2 cases).

[0035] The clinical manifestations of the patients were ordinary drug eruption, among which 10 cases were urticarial drug eruption, showing generalized wheal-like rash, which was difficult to subside wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of HLA-A*24:02 allele to detecting person drug eruption risk caused by metronidazole. The invention provides application of a substance for detecting whether persons have the HLA-A*24:02 allele or not to preparing a product for detecting or evaluating adverse drug reaction risk generated when persons respond to the metronidazole. Experiments show that the humanleukocyte antigen gene-HLA-A*24:02 allele is related to drug eruptionattacking caused by the metronidazole. The HLA-A*24:02 allele can serve as a marker gene for forecasting the drug eruption risk caused by the metronidazole.

Description

technical field [0001] The invention relates to the application of the HLA-A*24:02 allele in detecting the risk of drug eruption caused by metronidazole in humans in the field of biomedicine. Background technique [0002] Drug eruption refers to the adverse reactions of the skin and (or) mucous membranes caused by drugs entering the human body through various channels. It is the most common adverse drug reaction, with a reported incidence of 1-3% in the past. With the increasing incidence of drug eruption in my country year by year, it not only causes serious harm to personal health and economic loss, but also becomes an obstacle in public health that hinders the safety of clinical medication and the development of new drugs, and has become a research hotspot at home and abroad. Recent studies at home and abroad have revealed that the occurrence of drug eruptions caused by various drugs is related to the coding genes of individual human leukocyte antigens (HLA), and HLA alle...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/156
Inventor 骆肖群邢清和杨凡萍姜孟林
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com